ArticleERJ open research2026
Prognostic value of distance-saturation product in COPD: Korean nationwide cohort study.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The distance-saturation product (DSP), calculated by multiplying 6-min walk distance (6MWD) by lowest oxygen saturation, is a composite physiological marker of exercise capacity and gas exchange impairment. Although DSP has shown prognostic potential in Western COPD cohorts, its utility and optimal threshold in Asian populations remain unestablished. This study evaluated whether DSP <290 m·% predicts exacerbations and mortality in COPD, compared with the BODE index. Methods: We analysed 1995 patients with valid 6MWD data from the Korean COPD Subgroup Study, a nationwide prospective cohort. DSP was dichotomised at 290 m·% based on restricted cubic spline analyses. Primary outcomes were 3-year acute exacerbations (AEs) and all-cause mortality. Associations were evaluated using multivariable logistic, negative binomial and Cox regression models, with the BODE index as comparator. Results: Patients with DSP <290 m·% had more severe symptoms, worse airflow limitation and more frequent prior-year AEs. Low DSP was independently associated with more frequent severe (adjusted incidence rate ratios (aIRRs) 2.27-2.54) and moderate (aIRRs 1.42-1.52) exacerbations, with significantly increased moderate AE risk observed only in year 1 (aOR 1.60; 95% CI 1.05-2.45). Patients with low DSP also had higher 3-year mortality (9.2% Conclusions: DSP is a simple, scalable prognostic marker in COPD patients. A threshold of 290 m·% identifies patients at higher risk of exacerbations and mortality.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.